MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Wearing-off fluctuations"

  • MDS Virtual Congress 2021

    Registry Analysis (In Progress) to Evaluate Clinical Outcomes and Disease Burden of Advanced PD in Patients With Motor Fluctuations and Dyskinesia Managed With Oral Dopaminergic Therapies Versus Device-Aided Therapies

    W. Hu, O. Ladhani, P. Kukreja, A. Ramirez-Zamora (Gainesville, USA)

    Objective: To compare clinical outcomes of patients with Parkinson's disease (PD) with moderate and severe motor fluctuations or dyskinesia managed with oral dopaminergic medications vs…
  • MDS Virtual Congress 2021

    Indirect Treatment Comparison of Adjunctive Treatments for Patients with Parkinson’s Disease Experiencing Motor Complications

    D. Kremens, W. Oertel, R. Pahwa, R. Hauser, C. Lecureuil, R. Johnson, G. Went (Philadelphia, USA)

    Objective: Evaluate the comparative efficacy of treatment options for Parkinson's disease (PD) motor complications using indirect treatment comparison. Background: Amantadine delayed release/extended release (DR/ER) capsules…
  • MDS Virtual Congress 2021

    Influence of Dopamine Transporter Gene Polymorphism on Wearing Off

    CE. Mantese, V. Altmann, A. Schumacher-Schuh, M. Hutz, CRM. Rieder (Porto Alegre, Brazil)

    Objective: To study the influence of Dopamine transporter gene polymorphism on Wearing off (WO) through 19 items wearing off questionnaire (WOQ-19) Background: The dopamine transporter…
  • MDS Virtual Congress 2021

    Analysis of Amantadine formulations for OFF and Dyskinesia in Parkinson Disease

    W. Oertel, R. Pahwa, R. Hauser, M. Sale, G. Went (Marburg, Germany)

    Objective: Evaluate the effects of amantadine formulations on the treatment of OFF and dyskinesia in Parkinson’s patients. Background: There are currently three formulations of amantadine…
  • MDS Virtual Congress 2021

    Levodopa/carbidopa intestinal gel (LCIG) reduces fluctuations and shortens time to on without troublesome dyskinesia in advanced Parkinson’s Disease: Post-hoc analyses of 54-week LCIG-monotherapy trial

    R. Pahwa, J. Aldred, A. Merola, N. Gupta, E. Terasawa, V. Garcia-Horton, P. Kandukuri, Y. Jalundhwala, Y. Bao, O. Ladhani, S. Isaacson (Kansas City, USA)

    Objective: To assess the long-term effectiveness of LCIG monotherapy on reducing daily health-state fluctuations and time to on without troublesome dyskinesia (ONwoTD) after waking Background:…
  • MDS Virtual Congress 2021

    Safinamide Improves Pain in Parkinson´s Disease. Results from the SAFINONMOTOR Study.

    R. Yáñez, C. Labandeira, M. Cimas Hernando, I. Cabo, J. Paz González, M. Alonso Losada, M. González Palmás, C. Martínez, D. Santos García (Ourense, Spain)

    Objective: Our aim was to analyze the effectiveness of safinamide on pain in Parkinson´s disease (PD) patients from the SAFINONMOTOR (an open-label study of the…
  • MDS Virtual Congress 2021

    Risk factors for the onset of dyskinesia in patients with Parkinson’s disease exhibiting wearing-off phenomena: A 1-year observational study in Japan (J-FIRST)

    T. Mishima, SW. Chiu, H. Saiki, T. Yamaguchi, Y. Shimo, T. Maeda, H. Watanabe, K. Kashihara, M. Nomoto, N. Hattori, Y. Tsuboi (Fukuoka, Japan)

    Objective: To investigate the risk factors for the onset of dyskinesia in patients with Parkinson's disease (PD) exhibiting wearing-off phenomena. Background: Dyskinesia occurs during long-term…
  • MDS Virtual Congress 2021

    Personality dimensions could be predictive of quality-of-life outcome after deep brain stimulation of the sub-thalamic nucleus in Parkinson’s Disease

    M. Boussac, T. Danaila, A. Eusebio, E. Hainque, JC. Corvol, O. Rascol, C. Moreau, AS. Rolland, D. Devos, S. Ansquer, OL. Boukbiza, AR. Marques, D. Maltete, S. Drapier, B. Jarraya, L. Belamri, P. Burbaud, M. Meyer, T. Rouaud, B. Giordana, M. Tir, C. Brefel-Courbon (Toulouse, France)

    Objective: Our objective was to evaluate associations between personality dimensions and Quality of Life (QoL) amelioration after one year of Deep Brain Stimulation of the…
  • MDS Virtual Congress 2021

    Feasibility to Detect Parkinson’s Motor Symptoms with a Waist-Worn Parkinson’s Holter

    DRM. Rodriguez-Martin, CPL. Perez-Lopez, MP. Pié, JC. Calvet, ACM. Català, JCM. Cabestany, NC. Caballol, AB. Bayés (Cornellà de Llobregat, Spain)

    Objective: Analysis of the feasibility in the detection of Parkinson’s Motor Symptoms. Background: Usually, in current clinical practice, the physicians have a very limited slot…
  • MDS Virtual Congress 2021

    Should Amantadine DR/ER Be Considered Prior to Device-Aided Therapies for Parkinson’s Disease?

    R. Hauser, S. Goud, A. Formella (Tampa, USA)

    Objective: Evaluate delayed release/extended release amantadine (AMT DR/ER) capsules for motor complications in patients meeting 5-2-1 criteria for device-aided therapies (DAT) in advanced Parkinson disease.…
  • « Previous Page
  • 1
  • …
  • 11
  • 12
  • 13
  • 14
  • 15
  • …
  • 29
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley